Prospective randomized pilot study of Y90 +/- sorafenib as bridge to transplantation in hepatocellular carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Hepatocellular
  • Embolization, Therapeutic
  • Liver Neoplasms
  • Liver Transplantation
  • Niacinamide
  • Phenylurea Compounds
  • Yttrium Radioisotopes

abstract

  • The addition of sorafenib to Y90 necessitated dose reductions in all patients awaiting transplantation. Preliminary data suggest that the combination was associated with more peri-transplant biliary complications and potentially trended towards more acute rejections. Caution should be exercised when considering sorafenib in the transplant setting. Further investigation is warranted.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jhep.2014.03.023

PubMed ID

  • 24681342

Additional Document Info

start page

  • 309

end page

  • 17

volume

  • 61

number

  • 2